



REPORTED SALES vs. PRIOR PERIOD (\$MM)

	FIRST QUARTER				
	2013	2012	% Change		
			Reported	Operational ⁽¹⁾	Currency
CONSUMER SEGMENT ⁽²⁾					
<u>BABY CARE</u>					
US	\$ 103	99	4.0%	4.0%	-
Intl	461	441	4.5%	7.7%	-3.2%
WW	<u>564</u>	<u>540</u>	4.4%	7.0%	-2.6%
<u>ORAL CARE</u>					
US	158	155	1.9%	1.9%	-
Intl	245	232	5.6%	7.3%	-1.7%
WW	<u>403</u>	<u>387</u>	4.1%	5.1%	-1.0%
<u>OTC/NUTRITIONALS</u>					
US	436	381	14.4%	14.4%	-
Intl	747	723	3.3%	3.9%	-0.6%
WW	<u>1,183</u>	<u>1,104</u>	7.2%	7.6%	-0.4%
<u>SKIN CARE</u>					
US	453	453	0.0%	0.0%	-
Intl	449	454	-1.1%	-0.4%	-0.7%
WW	<u>902</u>	<u>907</u>	-0.6%	-0.2%	-0.4%
<u>WOMEN'S HEALTH</u>					
US	81	93	-12.9%	-12.9%	-
Intl	320	316	1.3%	4.9%	-3.6%
WW	<u>401</u>	<u>409</u>	-2.0%	0.8%	-2.8%
<u>WOUND CARE/OTHER</u>					
US	117	135	-13.3%	-13.3%	-
Intl	105	113	-7.1%	-6.1%	-1.0%
WW	<u>222</u>	<u>248</u>	-10.5%	-10.0%	-0.5%
TOTAL CONSUMER					
US	1,348	1,316	2.4%	2.4%	-
Intl	2,327	2,279	2.1%	3.8%	-1.7%
WW	<u>\$ 3,675</u>	<u>3,595</u>	2.2%	3.3%	-1.1%

See footnotes at end of schedule

REPORTED SALES vs. PRIOR PERIOD (\$MM)

	FIRST QUARTER				
	2013	2012	% Change		
			Reported	Operational ⁽¹⁾	Currency
PHARMACEUTICAL SEGMENT ^{(2) (4)}					
<u>IMMUNOLOGY</u>					
US	\$ 1,639	1,453	12.8%	12.8%	-
Intl	565	442	27.8%	30.1%	-2.3%
WW	2,204	1,895	16.3%	16.8%	-0.5%
<u>REMICADE</u>					
US	970	882	10.0%	10.0%	-
US Exports ⁽³⁾	349	378	-7.7%	-7.7%	-
Intl	281	261	7.7%	9.5%	-1.8%
WW	1,600	1,521	5.2%	5.5%	-0.3%
<u>SIMPONI</u>					
US	94	64	46.9%	46.9%	-
Intl	143	52	*	*	-3.3%
WW	237	116	*	*	-2.0%
<u>STELARA</u>					
US	226	129	75.2%	75.2%	-
Intl	120	92	30.4%	31.2%	-0.8%
WW	346	221	56.6%	57.0%	-0.4%
<u>OTHER IMMUNOLOGY</u>					
US	-	-	-	-	-
Intl	21	37	-43.2%	-42.9%	-0.3%
WW	21	37	-43.2%	-42.9%	-0.3%
<u>INFECTIOUS DISEASES</u>					
US	238	242	-1.7%	-1.7%	-
Intl	577	513	12.5%	13.5%	-1.0%
WW	815	755	7.9%	8.6%	-0.7%
<u>INCIVO</u>					
US	-	-	-	-	-
Intl	162	132	22.7%	24.9%	-2.2%
WW	162	132	22.7%	24.9%	-2.2%
<u>INTELENCE</u>					
US	47	43	9.3%	9.3%	-
Intl	42	37	13.5%	14.1%	-0.6%
WW	89	80	11.3%	11.6%	-0.3%
<u>PREZISTA</u>					
US	167	160	4.4%	4.4%	-
Intl	200	164	22.0%	22.3%	-0.3%
WW	367	324	13.3%	13.5%	-0.2%
<u>OTHER INFECTIOUS DISEASES</u>					
US	24	39	-38.5%	-38.5%	-
Intl	173	180	-3.9%	-3.0%	-0.9%
WW	197	219	-10.0%	-9.3%	-0.7%

REPORTED SALES vs. PRIOR PERIOD (\$MM)

	FIRST QUARTER				
	<u>2013</u>	<u>2012</u>	<u>% Change</u>		
			<u>Reported</u>	<u>Operational ⁽¹⁾</u>	<u>Currency</u>
<u>NEUROSCIENCE</u>					
US	746	674	10.7%	10.7%	-
Intl	998	973	2.6%	5.6%	-3.0%
WW	1,744	1,647	5.9%	7.7%	-1.8%
<u>CONCERTA/METHYLPHENIDATE</u>					
US	139	197	-29.4%	-29.4%	-
Intl	117	111	5.4%	6.8%	-1.4%
WW	256	308	-16.9%	-16.4%	-0.5%
<u>INVEGA</u>					
US	71	69	2.9%	2.9%	-
Intl	61	52	17.3%	22.0%	-4.7%
WW	132	121	9.1%	11.1%	-2.0%
<u>INVEGA SUSTENNA/ XEPLION</u>					
US	164	100	64.0%	64.0%	-
Intl	120	61	96.7%	96.0%	0.7%
WW	284	161	76.4%	76.1%	0.3%
<u>RISPERDAL CONSTA</u>					
US	106	113	-6.2%	-6.2%	-
Intl	229	248	-7.7%	-6.0%	-1.7%
WW	335	361	-7.2%	-6.0%	-1.2%
<u>OTHER NEUROSCIENCE</u>					
US	266	195	36.4%	36.4%	-
Intl	471	501	-6.0%	-1.8%	-4.2%
WW	737	696	5.9%	8.9%	-3.0%
<u>ONCOLOGY</u>					
US	199	107	86.0%	86.0%	-
Intl	595	489	21.7%	23.9%	-2.2%
WW	794	596	33.2%	35.0%	-1.8%
<u>VELCADE</u>					
US	-	-	-	-	-
Intl	353	353	0.0%	2.5%	-2.5%
WW	353	353	0.0%	2.5%	-2.5%
<u>ZYTIGA</u>					
US	161	100	61.0%	61.0%	-
Intl	183	100	83.0%	83.4%	-0.4%
WW	344	200	72.0%	72.2%	-0.2%
<u>OTHER ONCOLOGY</u>					
US	38	7	*	*	-
Intl	59	36	63.9%	68.7%	-4.8%
WW	97	43	*	*	-4.0%

REPORTED SALES vs. PRIOR PERIOD (\$MM)

	FIRST QUARTER				
	<u>2013</u>	<u>2012</u>	<u>% Change</u>		
			<u>Reported</u>	<u>Operational ⁽¹⁾</u>	<u>Currency</u>
<u>TOTAL OTHER</u>					
US	649	550	18.0%	18.0%	-
Intl	562	690	-18.6%	-17.5%	-1.1%
WW	<u>1,211</u>	<u>1,240</u>	-2.3%	-1.7%	-0.6%
<u>ACIPHEX/PARIET</u>					
US	103	96	7.3%	7.3%	-
Intl	49	126	-61.1%	-60.5%	-0.6%
WW	<u>152</u>	<u>222</u>	-31.5%	-31.2%	-0.3%
<u>PROCRIT/EPREX</u>					
US	233	204	14.2%	14.2%	-
Intl	145	172	-15.7%	-15.8%	0.1%
WW	<u>378</u>	<u>376</u>	0.5%	0.5%	0.0%
<u>XARELTO</u>					
US	158	27	*	*	-
Intl	-	-	-	-	-
WW	<u>158</u>	<u>27</u>	*	*	-
<u>OTHER</u>					
US	155	223	-30.5%	-30.5%	-
Intl	368	392	-6.1%	-4.4%	-1.7%
WW	<u>523</u>	<u>615</u>	-15.0%	-13.9%	-1.1%
<u>TOTAL PHARMACEUTICAL</u>					
US	3,471	3,026	14.7%	14.7%	-
Intl	3,297	3,107	6.1%	8.1%	-2.0%
WW	<u>\$ 6,768</u>	<u>6,133</u>	10.4%	11.4%	-1.0%

Supplemental Sales Information	2012				
	<u>Q1</u>	<u>Q2</u>	<u>Q3</u>	<u>Q4</u>	<u>Full Year</u>
<u>INCIVO</u>					
US	-	-	-	-	-
Intl	132	102	71	138	443
WW	<u>132</u>	<u>102</u>	<u>71</u>	<u>138</u>	<u>443</u>
<u>XARELTO</u>					
US	27	49	68	95	239
Intl	-	-	-	-	-
WW	<u>27</u>	<u>49</u>	<u>68</u>	<u>95</u>	<u>239</u>

See footnotes at end of schedule

REPORTED SALES vs. PRIOR PERIOD (\$MM)

	FIRST QUARTER				
	2013	2012	% Change		
			Reported	Operational ⁽¹⁾	Currency
MEDICAL DEVICES AND DIAGNOSTICS ⁽²⁾					
<u>CARDIOVASCULAR CARE</u>					
US	\$ 198	176	12.5%	12.5%	-
Intl	315	306	2.9%	6.2%	-3.3%
WW	513	482	6.4%	8.5%	-2.1%
<u>DIABETES CARE</u>					
US	283	352	-19.6%	-19.6%	-
Intl	317	318	-0.3%	0.9%	-1.2%
WW	600	670	-10.4%	-9.8%	-0.6%
<u>DIAGNOSTICS</u>					
US	248	253	-2.0%	-2.0%	-
Intl	229	259	-11.6%	-7.9%	-3.7%
WW	477	512	-6.8%	-4.9%	-1.9%
<u>INFECTION PREVENTION/OTHER</u>					
US	85	116	-26.7%	-26.7%	-
Intl	127	128	-0.8%	4.1%	-4.9%
WW	212	244	-13.1%	-10.5%	-2.6%
<u>ORTHOPAEDICS</u>					
US	1,261	783	61.0%	61.0%	-
Intl	1,124	710	58.3%	60.5%	-2.2%
WW	2,385	1,493	59.7%	60.7%	-1.0%
<u>SPECIALTY SURGERY</u>					
US	319	327	-2.4%	-2.4%	-
Intl	308	301	2.3%	4.7%	-2.4%
WW	627	628	-0.2%	1.0%	-1.2%
<u>SURGICAL CARE</u>					
US	531	593	-10.5%	-10.5%	-
Intl	977	1,032	-5.3%	-2.4%	-2.9%
WW	1,508	1,625	-7.2%	-5.4%	-1.8%
<u>VISION CARE</u>					
US	281	277	1.4%	1.4%	-
Intl	459	480	-4.4%	1.6%	-6.0%
WW	740	757	-2.2%	1.6%	-3.8%
<u>TOTAL MEDICAL DEVICES AND DIAGNOSTICS</u>					
US	3,206	2,877	11.4%	11.4%	-
Intl	3,856	3,534	9.1%	12.2%	-3.1%
WW	\$ 7,062	6,411	10.2%	11.9%	-1.7%

* Percentage greater than 100%

(1) Operational growth excludes the effect of currency

(2) Select areas (unaudited)

(3) Reported as U.S. sales

(4) Prior year amounts have been reclassified to conform to current year product disclosure